Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma

Next Previous
X
Search
Trial Profile

A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jul 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenvatinib (Primary) ; Sorafenib
  • Indications Liver cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms REFLECT
  • Sponsors Eisai Co Ltd

    • Most Recent Events

    • 04 Jun 2024 Results (n=167) assessing associations between ctDNA MUT status and ORR via Fisher's exact test or PFS/OS via Cox regression/log rank test, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
    • 06 Jun 2023 Results of post hoc analysis (n=1189) of patients with nonviral etiology from REFLECT presented at the 59th Annual Meeting of the American Society of Clinical Oncology
    • 20 Sep 2022 Results of sub-analysis assessing objective response as an independent predictor of overall survival in individuals with unresectable hepatocellular carcinoma receiving systemic anti-angiogenic therapy, published in the Journal of Hepatology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top